rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Foghorn Therapeutics Inc.

FHTX · Nasdaq

Health CareBiotechnologyNot moving yet

FHTX stood above a rising 150-day average in 18 of the last 52 weekly readings, and has been out of that trend for the last 7 weeks. It is 56.2% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 7
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
101 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 18 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders101+1 on the quarter
New · exited17 · 16
Reported value$219.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Flagship Pioneering, LLCunchanged · filed 14 Aug 202612,674,120$61.8M00.0%
BVF INCunchanged · filed 14 Aug 20265,842,000$28.5M00.0%
FMR LLCreduced · filed 13 Aug 20265,705,958$27.8M-341,240−5.6%
DEERFIELD MANAGEMENT COMPANY, L.P.unchanged · filed 14 Aug 20264,394,367$21.4M00.0%
BlackRock, Inc.added · filed 7 Aug 20262,626,832$12.8M+261,966+11.1%
RAYMOND JAMES FINANCIAL INCreduced · filed 14 Aug 20262,489,978$12.2M-112,404−4.3%
Euclidean Capital LLCunchanged · filed 14 Aug 20261,573,761$7.7M00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,494,611$7.3M-4780.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026910,866$4.4M+62,694+7.4%
Siren, L.L.C.unchanged · filed 13 Aug 2026720,720$3.5M00.0%
31 Mar 2023 – 30 Jun 2026
477399Mar 23Dec 23Dec 24Sep 25Jun 26

News

Everyone who traded it

B. Lynne Parshall Company insiderDirector · last 24 Jun 20260 · 0
Douglas G. Cole Company insiderDirector · last 24 Jun 20260 · 0
Ian F. Smith Company insiderDirector · last 24 Jun 20260 · 0
Michael Mendelsohn Company insiderDirector · last 24 Jun 20260 · 0
Neil Gallagher Company insiderDirector · last 24 Jun 20260 · 0
Scott Biller Company insiderDirector · last 24 Jun 20260 · 0
Simba Gill Company insiderDirector · last 24 Jun 20260 · 0
Stuart Duty Company insiderDirector · last 24 Jun 20260 · 0
Thomas J. Lynch Jr. Company insiderDirector · last 24 Jun 20260 · 0
Adrian Gottschalk Company insiderChief Executive Officer · last 10 Apr 20260 · 0
Ryan D. Maynard Company insiderChief Financial Officer · last 23 Feb 20260 · 0
Alfonso Quintas Cardama Company insiderChief Medical Officer · last 30 Jan 20260 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-279%
Free cash flow marginFY 2025 · to 31 Dec 2025-279%
Return on capital employedFY 2025 · to 31 Dec 2025-62.4%
Research spendFY 2025 · to 31 Dec 2025277%
Share count trendFY 2025 · to 27 Feb 20263.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$80.9M
Free cash flowFY 2025 · to 31 Dec 2025−$86.1M

Analyst forecasts

No analyst forecasts yet.